Previous 10 | Next 10 |
ADC Therapeutics ([[ADCT]] +0.6%) has entered into an agreement to jointly form a new company, Overland ADCT BioPharma Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital.Overland Pharmaceuticals to have a 51% stake and ADC Therapeu...
ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures NEW YORK , Dec. 15, 2020 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its clie...
ADC Therapeutics (ADCT) and Hillhouse Capital-backed Overland Pharmaceuticals, have jointly formed a new company, Overland ADCT BioPharma, to develop and commercialize ADC Therapeutics’ four antibody drug conjugate ((ADC)) candidates for hematologic and solid tumors, including lon...
- Hillhouse-backed Overland Pharmaceuticals to initially contribute $50 million to fund operations and development ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, today announced that the...
Bank of America reiterates a Buy rating on ADC Therapeutics ([[ADCT]] -2.8%) after taking in the company's drug data presentation at ASH and accompanying conference call. BofA's Ionca update: "An August 2020 cut of LOTIS-2, the pivotal ph 2 trial in relapsed or refractory (r/r) diffuse large ...
Lonca LOTIS 2 subgroup data include updated median duration of response of 12.58 months LOTIS 3 interim results highlight potential of Lonca in combination with ibrutinib in relapsed or refractory diffuse large B-cell lymphoma and mantle cell lymphoma patients Prelimin...
- Mehdi Hamadani, MD, Medical College of Wisconsin, to discuss data for lead candidate loncastuximab tesirine (Lonca) - Conference call and webcast to be held Monday, December 7, 2020, at 8:00 a.m. ET ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-fo...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Under priority review status, the FDA has accepted ADC Therapeutics' (ADCT) marketing application for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma ((DLBCL))Agency's action date is set at May 21, 2021.Lonca is also being evaluate...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...